Efficacy Observation of Interleukin-2 Combined with Cisplatin in the Treatment of Malignant Pleural Effusion
- VernacularTitle:细胞白介素-2联合顺铂治疗恶性胸腹水疗效观察
- Author:
Yanyan LI
;
Shuai WANG
;
Na CHANG
;
Wenjuan FU
;
Xiaoju ZHU
;
Ling TONG
;
Suyan LIU
- Keywords:
Interleukin-2;
Cisplatin;
Malignant pleural effusion
- From:
China Pharmacist
2017;20(5):851-853
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect and safety of interleukin-2 combined with cisplatin in the treatment of malignant pleural effusion.Methods: Totally 86 patients with malignant pleural effusion were randomly divided into the observation group (44 cases) and the control group (42 cases).The control group was treated with cisplatin, and the observation group was treated with interleukin-2 additionally.The treatment course was 3 weeks.The ascites relief, quality of life, survival status and tumor markers before and after the treatment, and the adverse drug reactions were compared between the groups.Results: The total ascites remission rate and the effective rate in the observation group were significantly higher than those in the control group (P<0.05).Compared with those before the treatment, CEA, CA19-9 and CA450 decreased significantly after the treatment in both groups (P<0.05), those in the observation group were significantly lower than those in the control group (P<0.05).After the treatment, the physiological function, physiological occupation, emotional function, body pain and the other life quality scores in the observation group were significantly higher than those in the control group (P<0.05).The 24-month survival rate in the observation group was significantly higher than that in the control group (P<0.05).There were no significant differences in adverse drug reactions between the groups (P>0.05).Conclusion: Interleukin-2 combined with cisplatin can effectively relieve ascites and improve quality of life, which can also prolong the survival time of patients.
